comparemela.com
Home
Live Updates
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland : comparemela.com
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences
Related Keywords
United States
,
United Kingdom
,
Switzerland
,
France
,
Turkey
,
French
,
Pierre Fabre
,
Sumitovant Biopharma
,
Jim Robinson
,
Maya Frutiger
,
Eric Ducournau
,
Alana Darden Powell
,
Anne Kerveillant
,
Urovant Sciences Gmb
,
Media Relations Pf Pharmaceuticals Direction
,
Corporate Communications
,
Pierre Fabre Group
,
Facebook
,
Urovant Sciences
,
Sumitovant Biopharma Ltd
,
Head Of Corporate Communications
,
Pierre Fabre Foundation
,
Overactive Bladder
,
Europe Economic Area
,
Sciences Gmbh
,
European Economic Area
,
Sub Saharan Africa
,
Eastern European
,
Chief Executive Officer
,
Benign Prostatic Hyperplasia
,
Sumitomo Pharma
,
Pierre Fabre Oncology
,
Pierre Fabre Dermatology
,
Pierre Fabre Oral
,
Product Information
,
Urovant Sciences Gmbh
,
Pierre Fabre Medicament
,
Darden Powell
,
Urovant
,
Ciences
,
Pierre
,
Sabre
,
M 233 Dicament
,
Winter
,
Exclusive
,
License
,
Agreement
,
Ommercialize
,
Vibegron
,
Treatment
,
Overactive
,
Ladder
,
European
,
Economic
,
Area
,
comparemela.com © 2020. All Rights Reserved.